Hybrid PET-MRI Imaging in Paediatric and TYA Brain Tumours: Clinical Applications and Challenges

Overview

Journal J Pers Med

Date 2020 Nov 13

PMID 33182433

Citations 5

Authors

Ananth Shankar

Jamshed Bomanji

Harpreet Hyare

Affiliations

Soon will be listed here.

Abstract

(1) Background: Standard magnetic resonance imaging (MRI) remains the gold standard for brain tumour imaging in paediatric and teenage and young adult (TYA) patients. Combining positron emission tomography (PET) with MRI offers an opportunity to improve diagnostic accuracy. (2) Method: Our single-centre experience of F-fluorocholine (FCho) and fluoro-L-phenylalanine (FDOPA) PET-MRI in paediatric/TYA neuro-oncology patients is presented. (3) Results: Hybrid PET-MRI shows promise in the evaluation of gliomas and germ cell tumours in (i) assessing early treatment response and (ii) discriminating tumour from treatment-related changes. (4) Conclusions: Combined PET-MRI shows promise for improved diagnostic and therapeutic assessment in paediatric and TYA brain tumours.

Citing Articles

Tryptophan Kynurenine Pathway-Based Imaging Agents for Brain Disorders and Oncology-From Bench to Bedside.

Stauff E, Xu W, Kecskemethy H, Langhans S, Kandula V, Averill L Biomolecules. 2025; 15(1).

PMID: 39858441 PMC: 11762981. DOI: 10.3390/biom15010047.

Advances in pediatric gliomas: from molecular characterization to personalized treatments.

Sathyakumar S, Martinez M, Perreault S, Legault G, Bouffet E, Jabado N Eur J Pediatr. 2024; 183(6):2549-2562.

PMID: 38558313 DOI: 10.1007/s00431-024-05540-4.

Update on the Use of PET/MRI Contrast Agents and Tracers in Brain Oncology: A Systematic Review.

Smeraldo A, Ponsiglione A, Soricelli A, Netti P, Torino E Int J Nanomedicine. 2022; 17:3343-3359.

PMID: 35937076 PMC: 9346926. DOI: 10.2147/IJN.S362192.

Integrin α6-Targeted Molecular Imaging of Central Nervous System Leukemia in Mice.

Zhang W, Li Y, Chen G, Yang X, Hu J, Zhang X Front Bioeng Biotechnol. 2022; 10:812277.

PMID: 35284414 PMC: 8905628. DOI: 10.3389/fbioe.2022.812277.

Magnetic Fields and Cancer: Epidemiology, Cellular Biology, and Theranostics.

Maffei M Int J Mol Sci. 2022; 23(3).

PMID: 35163262 PMC: 8835851. DOI: 10.3390/ijms23031339.

References

Kondo A, Ishii H, Aoki S, Suzuki M, Nagasawa H, Kubota K . Phase IIa clinical study of [F]fluciclovine: efficacy and safety of a new PET tracer for brain tumors. Ann Nucl Med. 2016; 30(9):608-618. DOI: 10.1007/s12149-016-1102-y. View

Henriksen O, Larsen V, Muhic A, Hansen A, Larsson H, Poulsen H . Simultaneous evaluation of brain tumour metabolism, structure and blood volume using [(18)F]-fluoroethyltyrosine (FET) PET/MRI: feasibility, agreement and initial experience. Eur J Nucl Med Mol Imaging. 2015; 43(1):103-112. DOI: 10.1007/s00259-015-3183-6. View

Dai W, Garcia D, de Bazelaire C, Alsop D . Continuous flow-driven inversion for arterial spin labeling using pulsed radio frequency and gradient fields. Magn Reson Med. 2008; 60(6):1488-97. PMC: 2750002. DOI: 10.1002/mrm.21790. View

Yan L, Sun Y, Zhao S, Hu Y, Han Y, Li G . Perfusion, Diffusion, Or Brain Tumor Barrier Integrity: Which Represents The Glioma Features Best?. Cancer Manag Res. 2019; 11:9989-10000. PMC: 6885544. DOI: 10.2147/CMAR.S197839. View

Giovannini E, Lazzeri P, Milano A, Gaeta M, Ciarmiello A . Clinical applications of choline PET/CT in brain tumors. Curr Pharm Des. 2014; 21(1):121-7. DOI: 10.2174/1381612820666140915120742. View

Tsouana E, Stoneham S, Fersht N, Kitchen N, Gaze M, Bomanji J . Evaluation of treatment response using integrated 18F-labeled choline positron emission tomography/magnetic resonance imaging in adolescents with intracranial non-germinomatous germ cell tumours. Pediatr Blood Cancer. 2015; 62(9):1661-3. DOI: 10.1002/pbc.25538. View

Kim S, Shim S . Diagnostic value of radiolabeled amino acid PET for detection of pseudoprogression of brain tumor after treatment: a meta-analysis. Nucl Med Commun. 2019; 40(9):965-972. DOI: 10.1097/MNM.0000000000001060. View

Boxerman J, Shiroishi M, Ellingson B, Pope W . Dynamic Susceptibility Contrast MR Imaging in Glioma: Review of Current Clinical Practice. Magn Reson Imaging Clin N Am. 2016; 24(4):649-670. DOI: 10.1016/j.mric.2016.06.005. View

Alongi P, Vetrano I, Fiasconaro E, Alaimo V, Laudicella R, Bellavia M . Choline-PET/CT in the Differential Diagnosis Between Cystic Glioblastoma and Intraparenchymal Hemorrhage. Curr Radiopharm. 2018; 12(1):88-92. DOI: 10.2174/1874471011666180817122427. View

10.

Hales P, DArco F, Cooper J, Pfeuffer J, Hargrave D, Mankad K . Arterial spin labelling and diffusion-weighted imaging in paediatric brain tumours. Neuroimage Clin. 2019; 22:101696. PMC: 6365981. DOI: 10.1016/j.nicl.2019.101696. View

11.

Calabria F, Barbarisi M, Gangemi V, Grillea G, Cascini G . Molecular imaging of brain tumors with radiolabeled choline PET. Neurosurg Rev. 2016; 41(1):67-76. DOI: 10.1007/s10143-016-0756-1. View

12.

Padma M, Jacobs M, Kraus G, McDowell P, Satter M, Adineh M . Radiation-induced medulloblastoma in an adult: a functional imaging study. Neurol India. 2004; 52(1):91-3. View

13.

Young R, Gupta A, Shah A, Graber J, Zhang Z, Shi W . Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma. Neurology. 2011; 76(22):1918-24. PMC: 3115805. DOI: 10.1212/WNL.0b013e31821d74e7. View

14.

Pollack I, Jakacki R . Childhood brain tumors: epidemiology, current management and future directions. Nat Rev Neurol. 2011; 7(9):495-506. DOI: 10.1038/nrneurol.2011.110. View

15.

Okada H, Weller M, Huang R, Finocchiaro G, Gilbert M, Wick W . Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015; 16(15):e534-e542. PMC: 4638131. DOI: 10.1016/S1470-2045(15)00088-1. View

16.

Filss C, Galldiks N, Stoffels G, Sabel M, Wittsack H, Turowski B . Comparison of 18F-FET PET and perfusion-weighted MR imaging: a PET/MR imaging hybrid study in patients with brain tumors. J Nucl Med. 2014; 55(4):540-5. DOI: 10.2967/jnumed.113.129007. View

17.

Fueger B, Czernin J, Cloughesy T, Silverman D, Geist C, Walter M . Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas. J Nucl Med. 2010; 51(10):1532-8. DOI: 10.2967/jnumed.110.078592. View

18.

Ellingson B, Bendszus M, Boxerman J, Barboriak D, Erickson B, Smits M . Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro Oncol. 2015; 17(9):1188-98. PMC: 4588759. DOI: 10.1093/neuonc/nov095. View

19.

Mentlein R, Hattermann K, Hemion C, Jungbluth A, Held-Feindt J . Expression and role of the cell surface protease seprase/fibroblast activation protein-α (FAP-α) in astroglial tumors. Biol Chem. 2010; 392(3):199-207. DOI: 10.1515/BC.2010.119. View

20.

Simon D, Fritzsche K, Thieke C, Klein J, Parzer P, Weber M . Diffusion-weighted imaging-based probabilistic segmentation of high- and low-proliferative areas in high-grade gliomas. Cancer Imaging. 2012; 12:89-99. PMC: 3335334. DOI: 10.1102/1470-7330.2012.0010. View